Keji Pharmaceutical - B (02171.HK) submitted the monthly securities report as of September 30, 2024 to the Hong Kong Exchange and Clearing Limited on October 7, 2024. The report indicates that the company's statutory/registered share capital and the number of issued shares remained unchanged that month, at 200,000,000,000 shares and 571,539,915 shares. In addition, under the 2019 stock-based incentive plan, the possible number of new shares that may be issued is 3,766,992 shares. The company confirms that all securities issuance or sale of treasury shares have been authorized by the board of directors and comply with all relevant listing rules and legal requirements.

Keji Pharmaceutical - B (02171.HK) submitted the monthly securities report as of September 30, 2024 to the Hong Kong Exchange and Clearing Limited on October 7, 2024. The report indicates that the company's statutory/registered share capital and the number of issued shares remained unchanged that month, at 200,000,000,000 shares and 571,539,915 shares. In addition, under the 2019 stock-based incentive plan, the possible number of new shares that may be issued is 3,766,992 shares. The company confirms that all securities issuance or sale of treasury shares have been authorized by the board of directors and comply with all relevant listing rules and legal requirements.